(Total Views: 288)
Posted On: 07/09/2021 3:49:19 PM
Post# of 281
NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiaries Showcase Products, Services at BIO Digital
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier international biotech partnering event held virtually on June 10-11 and 14-18, 2021, through its three subsidiaries. “While informative, the thrust of attending for companies like that of Predictive Oncology is networking and one-on-one sessions that can result in new partnerships or customers,” reads a recent article. “‘In previous conferences, Soluble Biotech has typically received more than a dozen requests for proposals, leading to new contracts for their main service of providing protein therapeutic formulations (i.e., formulations for vaccines, antibodies, virus-like particles),’ said Predictive Oncology CEO J. Melville Engle. He added that the Helomics unit is leveraging BIO’s one-on-one sessions to showcase its precision medicine discovery platform branded ‘PeDAL’… The conference allowed TumorGenesis to market its products and services specialized on culturing cancer cells from ovarian and breast cancers that more accurately mimic a patient’s tumors.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier international biotech partnering event held virtually on June 10-11 and 14-18, 2021, through its three subsidiaries. “While informative, the thrust of attending for companies like that of Predictive Oncology is networking and one-on-one sessions that can result in new partnerships or customers,” reads a recent article. “‘In previous conferences, Soluble Biotech has typically received more than a dozen requests for proposals, leading to new contracts for their main service of providing protein therapeutic formulations (i.e., formulations for vaccines, antibodies, virus-like particles),’ said Predictive Oncology CEO J. Melville Engle. He added that the Helomics unit is leveraging BIO’s one-on-one sessions to showcase its precision medicine discovery platform branded ‘PeDAL’… The conference allowed TumorGenesis to market its products and services specialized on culturing cancer cells from ovarian and breast cancers that more accurately mimic a patient’s tumors.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
